Brexpiprazole - An Overview
Prevent coadministration of pazopanib with strong CYP3A4 inhibitors if at all possible; if ought to coadminister, lower pazopanib dose to 400 mg/dayMinor (one)dasatinib and pazopanib both equally raise QTc interval. Insignificant/Significance Not known.Otesezonale, a BCRP inhibitor, may perhaps improve the consequences and hazard of toxicities of B